Golden logoGolden logo
Advanced Search
Jennifer Doudna

Jennifer Doudna

Is an American biochemist. Investor. Founder of Caribou Biosciences, Intellia Therapeutics and Mammoth Biosciences.

Doudna was an undergraduate student at Pomona College in Claremont, California, where she studied biochemistry.

She earned her Bachelor of Arts degree in Biochemistry in 1985. She chose Harvard Medical School for her doctoral study and earned a PhD in Biological Chemistry and Molecular Pharmacology in 1989.Her Ph.D. dissertation was on a system that increased the efficiency of a self-replicating catalytic RNA and was supervised by Jack W. Szostak.

Beginning in March 2020, Doudna organized an effort to use CRISPR-based technologies to address the COVID-19 pandemic along with Dave Savage, Robert Tjian, and other colleagues at the Innovative Genomics Institute (IGI), where they created a testing center.

This center processes more than 1,000 patient samples per day. Mammoth Biosciences announced a peer-reviewed validation of a rapid, CRISPR-based point of need COVID-19 diagnostic which is faster and less expensive than qRT-PCR based tests.

Cate is currently a Berkeley professor and works on gene-editing yeast to increase their cellulose fermentation for biofuel production.

Doudna and Cate have a son born in 2002 who now attends the University of California, Berkeley and is studying Electrical Engineering and Computer Science.


February 19, 1964
Jennifer Doudna was born in Washington, D.C..

Invested in


Further Resources



Joanna Glasner
September 21, 2021
Crunchbase News
Biotech companies--where female founders are better represented than in the overall tech sector--regularly go public at an earlier stage than other tech startups, commonly using public markets as a fundraising strategy rather than an exit. We look at whether these founding teams are actually getting more in early- and later-stage investment than the venture stats suggest.
August 6, 2021
Research aims to use two CRISPR enzymes to diagnose COVID in 20 minutes
August 6, 2021
Hindustan Times
The new technique, however, is not able to rival the sensitivity of RT-PCR but is at a stage where it can detect just a few copies of the virus per microliter of liquid. Currently, it is able to detect 30 copies per microliter -- sufficient to be used to survey people and limit spread of infections.
August 6, 2021
ANI News
California [US], August 6 (ANI): A research team led by scientists at the University of California, Berkeley, is aiming to develop a diagnostic test that is much faster and easier to deploy than the RT-PCR test which is today's gold standard for detecting COVID-19.
Carolyn Barber
July 17, 2021
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
Golden logo
By using this site, you agree to our Terms of Service.